Evidence map›Paper›PMID 20169186›Full record

ArticlePLoS pathogens2010

Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems.

Poornima Parameswaran, Ella Sklan, Courtney Wilkins, Trever Burgon, Melanie A Samuel, Rui Lu, K Mark Ansel, Vigo Heissmeyer, Shirit Einav, William Jackson and 19 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers.

0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed
41.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

161 citing papers in PubMed, 253 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting viral suppressor of RNAi confers anti-coronaviral activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Optimal delivery of RNA interference by viral vectors for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

101 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 11 institutions in 3 countries.

Poornima ParameswaranDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California, United States of America.
Ella Sklan
Courtney Wilkins
Trever Burgon
Melanie A Samuel
Rui Lu
K Mark Ansel
Vigo Heissmeyer
Shirit Einav
William Jackson
Tammy Doukas
Suman Paranjape
Charlotta Polacek
Flavia Barreto dos Santos
Roxana Jalili
Farbod Babrzadeh
Baback Gharizadeh
Dirk Grimm
Mark Kay
Satoshi Koike
Peter Sarnow
Mostafa Ronaghi
Shou-Wei Ding
Eva Harris
Marie Chow
Michael S Diamond
Karla Kirkegaard
Jeffrey S Glenn
Andrew Z Fire
Stanford University · USStanford Medicine · USUniversity of California, Berkeley · USUniversity of Arkansas for Medical Sciences · USUniversity of California, Riverside · USWashington University in St. Louis · USBerkeley Public Health Division · USHelmholtz Zentrum München · DEPediatrics and Genetics · USTokyo Metropolitan Institute of Medical Science · JPUniversity of California, San Francisco · US

Funding

Virology and Smallpox VaccinationsU54AI057160 · NIAID · WASHINGTON UNIVERSITY · PI OLDSTONE, MICHAEL B · 2003 to 2013
$80.9M
MOLECULAR BASIS OF HOST-PARASITE INTERACTIONT32AI007328 · NIAID · STANFORD UNIVERSITY · PI JUSTIN L SONNENBURG · 1987 to 2026
$11.9M
GENE REGULATION DURING EARLY DEVELOPMENT OF C. ELEGANSR01GM037706 · NIGMS · STANFORD UNIVERSITY · PI FIRE, ANDREW Z. · 1987 to 2018
$11.0M
RNAi for the Treatment of Viral HepatitisR01AI071068 · NIAID · STANFORD UNIVERSITY · PI KAY, MARK A · 2006 to 2020
$6.7M
Roles for microRNA-122 in hepatitis C virus RNA amplificationR01AI069000 · NIAID · STANFORD UNIVERSITY · PI SARNOW, PETER · 2006 to 2022
$6.2M
Gene Silencing as an Antiviral Defense in Animal CellsR01AI052447 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI DING, SHOU-WEI · 2003 to 2016
$6.0M
Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseasesR37AI071068 · NIAID · STANFORD UNIVERSITY · PI Mark A Kay · 2021 to 2026
$4.3M
HCV NS5A: Molecular Virology and Antiviral TargetR01DK064223 · NIDDK · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2004 to 2010
$1.5M
Role of cis &trans factors in dengue virus translationR01AI052324 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI HARRIS, EVA · 2004 to 2008
$1.4M
Novel Antiviral Targets in Hepatitis C virus NS4BR01DK066793 · NIDDK · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2004 to 2007
$1.4M
Novel antviral targets in Hepatitis C virus NS4B proteinK08AI079406 · NIAID · STANFORD UNIVERSITY · PI EINAV, SHIRIT · 2008 to 2012
$653k
Roles for virus-derived circular RNAs during RNA virus infectionsR56AI069000 · NIAID · STANFORD UNIVERSITY · PI SARNOW, PETER · 2025 to 2025
$634k
NCRR NIH HHS 1S10RR022982-01NCRR NIH HHS S10 RR022982NIAID NIH HHS AI052324NIAID NIH HHS AI069000NIAID NIH HHS AI071068NIAID NIH HHS K08 AI079406NIAID NIH HHS K08-AI079406-01NIAID NIH HHS R01 AI052324NIAID NIH HHS R01 AI052447NIAID NIH HHS R01 AI069000NIAID NIH HHS R01 AI071068NIAID NIH HHS R37 AI071068NIAID NIH HHS R56 AI069000NIAID NIH HHS T32 AI007328NIAID NIH HHS U54 AI057160NIDDK NIH HHS R01 DK064223NIDDK NIH HHS R01 DK066793NIGMS NIH HHS R01 GM037706NIGMS NIH HHS R0I GM37706
6 · The paper itself

Abstract

We have used multiplexed high-throughput sequencing to characterize changes in small RNA populations that occur during viral infection in animal cells. Small RNA-based mechanisms such as RNA interference (RNAi) have been shown in plant and invertebrate systems to play a key role in host responses to viral infection. Although homologs of the key RNAi effector pathways are present in mammalian cells, and can launch an RNAi-mediated degradation of experimentally targeted mRNAs, any role for such responses in mammalian host-virus interactions remains to be characterized. Six different viruses were examined in 41 experimentally susceptible and resistant host systems. We identified virus-derived small RNAs (vsRNAs) from all six viruses, with total abundance varying from "vanishingly rare" (less than 0.1% of cellular small RNA) to highly abundant (comparable to abundant micro-RNAs "miRNAs"). In addition to the appearance of vsRNAs during infection, we saw a number of specific changes in host miRNA profiles. For several infection models investigated in more detail, the RNAi and Interferon pathways modulated the abundance of vsRNAs. We also found evidence for populations of vsRNAs that exist as duplexed siRNAs with zero to three nucleotide 3' overhangs. Using populations of cells carrying a Hepatitis C replicon, we observed strand-selective loading of siRNAs onto Argonaute complexes. These experiments define vsRNAs as one possible component of the interplay between animal viruses and their hosts.

Indexed as

AnimalsInvertebratesMicroRNAsRNA, Small InterferingRNA, ViralRNA VirusesRNA Virus InfectionsVertebratesMicroRNAsRNA, Small InterferingRNA, Viral

Identifiers

PMID20169186
PMCPMC2820531
OpenAlexW2133924996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.